Opinion|Videos|May 29, 2024
NURE-COMBO: Patient Population, Regimen, and Efficacy in MIBC
Author(s)Neal Shore, MD
Neal Shore, MD, FACS, describes the patient population and treatment regimen evaluated in the NURE-COMBO phase 2 trial of neoadjuvant nivolumab plus nab-paclitaxel followed by adjuvant nivolumab in muscle-invasive bladder cancer (MIBC), and discusses the key efficacy results of pathologic complete response and major pathologic response rates.
Advertisement
Episodes in this series
Video content above is prompted by the following question(s):
- Describe the patient population and treatment regimen evaluated in the NURE-COMBO phase 2 trial of neoadjuvant nivolumab plus nab-paclitaxel followed by adjuvant nivolumab in MIBC. What were the key efficacy results in terms of pathologic complete response and major pathologic response rates?
Advertisement
Related to this article
A systemic sclerosis inception cohort and 17-study meta-analysis found a nearly 5-fold increase in lung cancer risk.
A rare case of soft-tissue sarcoma spreading to the heart shows how multimodal imaging guided diagnosis and care in a 36-year-old man.
Sustainable models require asking what a result shows, what design produced it, and whether the design was built to measure value or just produce a number.
As AI proliferates, patients, caregivers, and others outside the medical world are using its tools to deal with cancer, but not always in obvious ways.
Advertisement
Advertisement
Trending on AJMC
1
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
2
Systemic Sclerosis Linked to Dramatic Rise in Lung Cancer Risk
3
VBC Risk Is Outpacing Provider Readiness, CMS Must Act
4
Traditional Medicare OOP Cap Could Lower Costs, Raise Federal Spending
5